

International Summit on **GENOMICS AND PROTEOMICS CONFERENCE**

September 19-20, 2022 | Webinar

Stem cell therapy in ischemic stroke**Rahul jena and Minollie silva***Bharati Vidyapeeth Medical College, India*

Stroke is the second leading cause of death worldwide. In many Western countries, it is believed that one in every four people will have a stroke by the end of their lives. Currently, the only two recommended treatments for ischemic stroke are IV thrombolysis (rtPA) and endovascular thrombectomy. Despite this, nearly 60% of patients do not achieve functional independence three months after endovascular thrombectomy, possibly due to the surrounding narrow ischemic penumbra. Patients are frequently rendered disabled due to the time it takes to regain certain functions. Hence, there is an urgent need for alternative novel therapeutic modalities for stroke. One such method is stem cell therapy, a highly successful therapeutic modality which has successfully treated a number of pathological conditions. Stem cells have the added component of having the potential of prolonging the therapeutic window for stroke, the importance of which cannot be overstated, aside from neuroinflammatory cytokine modulation. This review assesses the latest studies analyzing the role of various types of stem cells in stroke treatment, many of which have shown promising results. What remains to be seen is the ideal route of administration, dosage, and timing to maximize the benefits to the patient, for which larger scale studies are required.

Biography

Rahul Jena is a final year medical student at Bharati Vidyapeeth Medical College, Pune. He is interested in internal medicine, neurology, and global health. He currently has 3 narrative reviews published and is actively involved in other research projects.